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Viral infections are able to induce autoimmune inﬂammation in the heart. Here, we investigated the role of virus-activated
Toll-like receptor (TLR)3 and its adaptor TRIF on the development of autoimmune coxsackievirus B3 (CVB3) myocarditis in
mice. Although TLR3- or TRIF-deﬁcient mice developed similarly worse acute CVB3 myocarditis and viral replication compared
to control mice, disease was signiﬁcantly worse in TRIF compared to TLR3-deﬁcient mice. Interestingly, TLR3-deﬁcient mice
developed an interleukin (IL)-4-dominant T helper (Th)2 response during acute CVB3 myocarditis with elevated markers of
alternative activation, while TRIF-deﬁcient mice elevated the Th2-associated cytokine IL-33. Treatment of TLR3-deﬁcient mice
with recombinant IL-33 improved heart function indicating that elevated IL-33 in the context of a classic Th2-driven response
protects against autoimmune heart disease. We show for the ﬁrst time that TLR3 versus TRIF deﬁciency results in diﬀerent Th2
responses that uniquely inﬂuence the progression to chronic myocarditis.
1.Introduction
Heart failure (HF) is the end consequence of a number of
cardiovascular diseases including myocarditis and dilated
cardiomyopathy (DCM). In spite of advances in diagnosis
and treatment, HF remains a growing medical problem asso-
ciated with major hospitalization, mortality, and poor prog-
nosis [1]. Myocarditis is an autoimmune disease that is res-
ponsibleforaroundhalfofallDCMcasesintheUnitedStates
[2–4]. A recent long-term study of myocarditis patients re-
vealed that inﬂammation was the best predictor for the pro-
gression to HF following acute myocarditis [5]. Viruses like
coxsackievirus B3 (CVB3) are often detected in patient myo-
cardial biopsies [3, 6], and antiviral treatments such as inter-
feron (IFN)-β reduce inﬂammation and HF in animal
models and patients [7, 8], implying that viral infections are
animportantcauseofmyocarditiscasesthatleadtoHF.Viral
infections including CVB3 are able to induce autoimmune
myocarditis that progresses to DCM in susceptible strains of
mice [9, 10].
Toll-like receptor (TLR)3 binds to double-stranded RNA
and inhibits viral replication by upregulating IFNs [11, 12].
TLR3 and TLR4 uniquely signal through TIR domain-con-
taining adaptor protein-inducing IFN-β (TRIF) at the endo-
somal surface [12]. Recently, TLR3 polymorphisms in a pa-
tient population were associated with an increased occur-
rence of viral myocarditis and DCM [13]. Previously, TLR3-
or TRIF-deﬁcient mice were found to develop increased
viral replication and acute myocarditis [11, 14]. Because
TRIF participates in TLR3 and TLR4 signaling and TLR3 is
known to protect against CVB3 myocarditis [14] while TLR4
increases disease [15], we were interested in determining
whether TLR3- and TRIF-deﬁcient mice developed similar
disease.
To examine the eﬀect of TLR3 versus TRIF deﬁciency on
myocarditis, DCM, and HF, we used an autoimmune model2 Clinical and Developmental Immunology
of CVB3 myocarditis where mice receive infectious virus and
heart proteins [9, 16]. We found that TLR3-deﬁcient mice
developed a classic T helper (Th)2 response with increased
interleukin (IL)-4 and markers of alternative activation dur-
ing acute CVB3 myocarditis, while TRIF-deﬁcient mice did
not. Although both knockout strains developed similarly
worse acute CVB3 myocarditis and viral replication compar-
edtowild-type(WT)mice,diseasewassigniﬁcantlyworsein
the absence of TRIF compared to TLR3. Our results indicate
that TLR3 protects against CVB3 myocarditis by increasing
IFN-γ and decreasing a classic IL-4-driven Th2 response,
while TRIF protects by increasing IFN-β and decreasing the
Th2-associated cytokine IL-33. Treatment of WT mice with
recombinant (r)IL-33 increased CVB3 myocarditis and im-
paired cardiac function. However, in the context of an IL-
4-skewed Th2 response (i.e., TLR3−/−), rIL-33 treatment
prevented cardiac dysfunction. We show for the ﬁrst time
that TLR3 versus TRIF deﬁciency results in diﬀerent Th2
responses that uniquely inﬂuence the progression to chronic
myocarditis.
2.MaterialsandMethods
2.1. Experimental Model. Wild-type C57BL/6 (BL/6),
B6.129, TLR3-(B6; 129S1-Tlr3tm1Flv/J)-deﬁcient
(TLR3−/−) and TRIF-(C57BL/6-Ticam1Lps2/J)-deﬁcient
(TRIF−/−) mice were obtained from The Jackson Labora-
tory (Bar Harbor, ME). Mice were maintained under patho-
gen-free conditions in the animal facility at Johns Hopkins
School of Medicine, and approval was obtained from the
Animal Care and Use Committee of the Johns Hopkins Uni-
versity for all procedures. CVB3 (Nancy strain) was obtained
from the American Type Culture Collection (ATCC, VA),
grown in Vero cells (ATCC) and passaged through the heart
as described previously [16]. Mice inoculated ip with unin-
fected cardiac tissue supernatant diluted in PBS, or PBS
alone, do not develop myocarditis (data not shown). Eight-
to-ten-week-old male mice were inoculated with 103 PFU
of heart-passaged CVB3 containing infectious virus and
heart tissue diluted in sterile PBS or PBS alone ip and tissues
collected at day 10 (acute myocarditis) or day 35 (chronic
myocarditis) pi as described previously [16]. Recombinant
rIL-33 (1μg/0.1mL, Cat#3626-ML) from R&D Systems
(Minneapolis, MN) was diluted in sterile PBS, or PBS only
was injected ip on days 1, 3, 5, 7, and 9 pi following CVB3
injection on day 0. All experiments were conducted three or
more times with 7 to 12 mice per group except for rIL-33
treatment of TLR3-deﬁcient mice.
2.2. Histology. Hearts were ﬁxed in 10% buﬀered formalin
and stained with haematoxylin and eosin (H&E) to assess
inﬂammation. Myocarditis was assessed as the percentage of
the heart section with inﬂammation compared to the overall
size of the heart section using a microscope eyepiece grid
according to [15]. The development of DCM was assessed
by gross observation of histology sections at low magniﬁ-
cation and by pressure-volume relationships, as previously
described [17, 18].
2.3. Cardiac Function. Cardiac function was assessed by pre-
ssure-volume catheter (1.2F Scisense Inc., London, ON)
placed in the left ventricle via the apex in open-chest mice
anesthetized with 3% isoﬂurane (Baxter, Deerﬁeld, IL), as
previously described [19, 20].
2.4. Plaque Assay. Hearts from individual mice were homog-
enized at 10% weight/volume in 2% minimal essential med-
ium (MEM) (MediaTech, Manassas, VA) and individual
supernatants used in plaque assays to determine the level of
infectious virus, as previously described [15] .V i r u sl e v e l sa r e
expressed as the mean plaque-forming unit (PFU)/g tissue ±
standard error of mean (SEM), and the limit of detection is
10 PFU/g of tissue.
2.5. ELISA. Hearts were homogenized at 10% weight/vol-
ume in 2% MEM and individual supernatants used in ELISA
[15, 17]. Cytokines were determined in homogenized super-
natants using R&D Systems ELISA kits (Minneapolis, MN),
according to the manufacturer’s instructions. Levels were ex-
pressed as pg/g of heart tissue ± SEM.
2.6. RNA Extraction and qRT-PCR. Hearts and spleens were
harvested and ﬂash frozen in liquid nitrogen and stored at
−80◦C. Tissues were homogenized in 2mL TRIzol (Invitro-
gen,Carlsbad,CA)accordingtothemanufacturer’sprotocol.
The PureLink Micro-to-Midi Total RNA Puriﬁcation System
(Invitrogen) was used for extraction and puriﬁcation of
RNA. RNA was quantiﬁed using a NanoDrop spectropho-
tometer and quality assessed by RNA Nano LabChip analysis
on an Agilent BioAnalyzer 2100 (Agilent Technologies, Santa
Clara,CA).TotalRNAfromheartsorspleens wasassessedby
quantitative real-time (qRT) PCR using Assay-on-Demand
primers and probe sets and the ABI 7000 Taqman System
from Applied Biosystems (Carlsbad, CA). Data were normal-
ized to hypoxanthine phosphoribosyltransferase 1 (HPRT)
according to [21]. There was no signiﬁcant diﬀerence in
HPRT expression in the heart or spleen before or after infec-
tion. The mRNA data are presented as a relative gene expre-
ssion (RGE). RGE is calculated as the ratio of target gene
expression(foldchangeofmRNAofinterest)tothenormali-
zation control gene expression (fold change of normalization
control mRNA).
2.7. Statistical Analysis. Two-group analysis of normally dis-
tributed data was performed by Student’s t-test. The Mann-
Whitney U-test was used to evaluate nonparametric data
comparing two groups. Multiple comparisons were analyzed
by ANOVA with a Bonferroni correction. A value of P<0.05
was considered signiﬁcant.
3. Results
3.1. Inﬂammation and Viral Replication Increase in a Similar
Manner in TLR3- or TRIF-Deﬁcient Mice during Acute CVB3
Myocarditis. Because TRIF participates in TLR3 and TLR4
signaling and TLR3 is known to protect against CVB3 myo-
carditis [14] while TLR4 increases disease [15], we wereClinical and Developmental Immunology 3
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Figure 1: Inﬂammation and viral replication increase in a similar manner in TLR3-deﬁcient (TLR3−/−) or TRIF−/− mice during acute
CVB3myocarditis.(a)TLR3−/−micedevelopedincreasedinﬂammationandviralreplicationatday10picomparedtoWTB6.129controls.
(a)RepresentativehistologysectionsofinﬂammationinWTandTLR3−/−heartsstainedwithH&E(top),magniﬁcation ×64.(b)TRIF−/−
mice develop increased inﬂammation and viral replication at day 10pi compared to WT BL/6 controls. (b) Representative histology sections
of inﬂammation in WT and TRIF−/− hearts stained with H&E (top), magniﬁcation ×64. Data show the mean ± SEM of at least three
separate experiments using 7 to 12 mice/group. ∗∗: P<0.01, ∗∗∗: P<0.001.
interestedindetermining whetherTLR3-andTRIF-deﬁcient
mice developed similar disease. As expected, there was a sig-
niﬁcant increase in viral replication and acute myocarditis at
day 10pi in TLR3- or TRIF-deﬁcient mice compared to WT
controls (Figure 1), conﬁrming previous reports [11, 14].
When we began these studies, only TLR3-deﬁcient mice on
a B6.129 background were available, and it was only very
recently that Jackson Laboratories began to oﬀer TLR3-def-
icient mice on a BL/6 background. Our preliminary studies
with TLR3-deﬁcient mice on a BL/6 background provide
similar results as we found with TLR3-deﬁcient B6.129 mice
(data not shown), but we have not performed a complete
analysisofBL/6TLR3-deﬁcientmice.Importantly,bothBL/6
and B6.129 WT strains had a very similar level of inﬂamma-
tion and viral replication in the heart at day 10pi (Figure 1).
Based on these results, it appears that activation of TLR3 and
TRIF inhibits CVB3 myocarditis in a similar manner.
3.2. Deﬁciency in TLR3 or TRIF Has a Diﬀerent Eﬀect on
Survival. Although the role of TLR3- or TRIF-deﬁciency
appeared similar when examining the severity of viral repli-
cation and acute inﬂammation in the heart at day 10pi
(Figure 1), their eﬀect on survival was distinctly diﬀerent
(Figure 2). Note that with this autoimmune CVB3 model of
myocarditis nearly 100% of WT BL/6, B6.129, or BALB/c
mice survive to day 35pi [16, 17]. Most WT, and TLR3-
deﬁcient mice survived to day 35pi (Figure 2). In contrast,
40% of TRIF-deﬁcient mice died by day 25pi (P<0.001).
These ﬁndings suggest that there are distinct diﬀerences in4 Clinical and Developmental Immunology
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Figure 2: Survival diﬀers between TLR3-deﬁcient (TLR3−/−) and TRIF−/− mice with CVB3 myocarditis/DCM. (a) Survival of TLR3−/−
mice compared to WT B6.129 controls (TLR3−/− versus WT, n = 77/group). (b) Survival of TRIF−/− mice compared to WT BL/6 controls
(TRIF−/− versus WT, n = 45/group), ∗∗∗: P<0.001.
TLR3- versus TRIF-deﬁcient mice that aﬀect progression to
chronic disease and HF.
3.3. TRIF-Deﬁcient Mice Develop Signiﬁcantly Worse Heart
Function at Day 10pi. Next, we compared heart function in
TLR3- versus TRIF-deﬁcient mice during acute CVB3 myo-
carditis by echocardiography. We found that although TLR3-
or TRIF-deﬁcient mice developed signiﬁcantly worse heart
function compared to their WT controls (Figures 3(a)
and 3(b), resp.), that TRIF-deﬁcient mice were signiﬁ-
cantlyworsecomparedtoTLR3-deﬁcientmice(Figure 3(c)).
Importantly, there were no diﬀerences in heart function as
assessed by echocardiography during acute CVB3 myocardi-
tis between WT B6.129 or BL/6 strains (Figure 3). Echocar-
diography in-dicated that TRIF-deﬁcient mice were already
dilated by day 10 pi (see left ventricular end diastolic
dimension/LVEDD) (Figure 3). Dilation in TRIF-deﬁcient
mice during acute CVB3 myocarditis was also observed by
histology and is indicated by a thinning of the left ventricular
wall in TRIF-deﬁcient mice that was not observed in TLR3-
deﬁcient mice at day 10pi (Figure 4). In susceptible mouse
strains like BALB/c or A/J, dilation does not usually develop
until day 35pi, while B6.129 and BL/6 strains are resistant to
the development of DCM in this model [16]. These ﬁndings
in-dicate that TRIF is critically important in protecting
against progression to DCM in resistant strains of mice like
BL/6 and B6.129.
3.4. TLR3 versus TRIF Deﬁciency Aﬀects Heart Function
Diﬀerently during Acute and Chronic CVB3 Myocarditis. Fur-
ther evidence that TLR3 and TRIF have separate roles in
regulating the progression from myocarditis to DCM was
obtained by comparing acute and chronic heart function
using pressure-volume relationships in WT and knockout
mice. Recall that B6.129 and BL/6 WT mice are resistant
strainsthatdonotdevelopthechronicphaseofautoimmune
CVB3 myocarditis and DCM [16]. We conﬁrmed that these
WT strains did not develop DCM in this study (Table 1 and
Figure 5, see EDV day 35pi versus day 0). No signiﬁcant
diﬀerence was observed in the severity of acute myocarditis
between B6.129 and BL/6 WT mice at day 10pi (Figure 1),
orintheircardiacfunctionpriortoinfection(day0)oratday
1 0a n d3 5 p if o rm o s tp a r a m e t e r s( Table 1 and Figure 5).
Thus, cardiac function in WT B6.129 and BL/6 mice during
acute and chronic CVB3 myocarditis is nearly identical
(Table 1).
In contrast, a comparison of TLR3 to TRIF-deﬁcient
mice using pressure-volume relations demonstrated signif-
icantly diminished left ventricular (LV) function and increa-
sed dilation in TRIF-deﬁcient mice at day 10 and 35pi
(Figure 5). End diastolic volume (EDV) is a measure of LV
dilation and was signiﬁcantly increased in TRIF-deﬁcient
mice by day 10 and 35pi compared to TLR3-deﬁcient mice,
which were not dilated similar to WT B6.129 and BL/6 mice
(Figure 5(b)). Thus, once TRIF-deﬁcient mice became
dilated at day 10pi, they remained dilated to day 35pi
(Figure 5(b), see EDV). During acute myocarditis, ejection
fraction (EF) was signiﬁcantly lower in TRIF- than TLR3-
deﬁcient mice (26% ± 2.8 versus 48% ± 4.7, P<0.05).
An EF less than 40% indicates the risk for heart failure [22].
The peak rate of pressure rise (dP/dT Max) was signif-
icantly lower in TRIF-deﬁcient mice compared to TLR3-
deﬁcient mice (5535 ± 688 versus 8803 ± 760mmHg/s,
P<0.05). End systolic pressure (ESP) was signiﬁcantly
lower in TRIF- compared to TLR3-deﬁcient mice dur-
ing acute myocarditis (65 ± 4.5v e r s u s9 6± 4.7mmHg,
P<0.05). Thus, many important functional parameters
were signiﬁcantly worse in TRIF- compared to TLR3-
deﬁcient mice by day 10pi that persisted to day 35pi, but
these changes were not observed in WT mice (Figure 5
and Table 1). In fact, most functional parameters were not
signiﬁcantly diﬀerent between BL/6 and B6.129 mice at base-
line (day 0), day 10, or day 35pi (Table 1). Thus, TRIF-deﬁ-
cient mice rapidly progressed to DCM and HF (e.g., low EF
and reduced survival), while TLR3-deﬁcient mice did not.
3.5. TLR3- and TRIF-Deﬁcient Mice Diﬀer in the Type of Th2
Response Induced during Acute Myocarditis. Wild-type BL/6Clinical and Developmental Immunology 5
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Figure 3: TRIF-deﬁcient mice develop signiﬁcantly worse heart function at day 10 pi. Echocardiography was used to assess heart function
in (a) TLR3-deﬁcient (TLR3−/−) versus WT B6.129 mice, (b) TRIF-deﬁcient (TRIF−/−) versus WT BL/6 mice, or (c) TLR3- versus TRIF-
deﬁcient mice. LVEDD, left ventricular end diastolic dimension; LVESD, left ventricular end systolic dimension; FS, fractional shortening;
EF, ejection fraction. Data show the mean ± SEM of at least three separate experiments using 7 to 12 mice/group. ∗: P<0.05; ∗∗: P<0.01;
∗∗∗: P<0.001.
and B6.129 mice characteristically produce Th1-type cyto-
kines in response to infections or other stimuli. Because
TLR3-andTRIF-deﬁcientmiceareknowntohaveadefective
Th1 response (i.e., reduced IFNs) following CVB3 infection
[11, 14], we examined whether the Th1/Th2 balance had
shifted in TLR3- and TRIF-deﬁcient mice during acute
myocarditis at day 10pi by examining cytokine levels in the
heart by ELISA. Previous reports had not described the type
of Th2 response TLR3- or TRIF-deﬁcient mice develop
during CVB3 myocarditis [11, 14], and since susceptibility
to chronic autoimmune myocarditis is dependent on a
Th2-type immune response [16, 17], we were interested
in determining whether a shift had occurred. We found that
TLR3-deﬁcient mice had signiﬁcantly increased IL-4 (P =
0.03) and decreased IFN-γ (P = 0.03) levels in the heart at
day 10pi (Figure 6), suggesting a shift to a Th2 response. In
contrast, TRIF-deﬁcient mice developed a diﬀerent type of
Th2 response characterized by signiﬁcantly reduced IFN-β
(a Th1 cytokine) (P = 0.009) and increased IL-33 (a Th2
cytokine) (P = 0.007) (Figure 6). To our knowledge, there
are no reports describing that TLR3- or TRIF-deﬁcient mice
develop diﬀerent types of Th2 responses.
Although the level of myocarditis, viral replication, and
cardiac function can be compared between diﬀerent experi-
ments, a direct comparison of cytokines in WT mice should
not be made because cytokine levels vary considerably bet-
ween experiments (even in the same mouse strain) due to
diﬀerences in processing the samples. So even though it
appears as if BL/6 mice have higher levels of IL-4 and
IFN-β duringacutemyocarditis(Figure 6,WTforTRIF −/−)6 Clinical and Developmental Immunology
B6.129 TLR3−/− (a) BL/6 TRIF−/− (b)
Figure 4: TRIF-deﬁcient (TRIF−/−) mice develop DCM by day 10 pi, but TLR3−/− mice do not. Representative histology sections of
(a) TLR3−/− compared to WT B6.129 controls at day 10 pi, magniﬁcation ×5. (b) Representative histology sections displaying dilation in
TRIF−/− compared to WT BL/6 mice at day 10 pi, magniﬁcation ×5.
compared to B6.129 mice (Figure 6, WT for TLR3−/−), this
may only be an artifact of processing. We did not conduct
an experiment to directly compare Th1 versus Th2 cytokine
levels in WT BL/6 versus B6.129 mice. Thus, the only valid
comparisonforcytokinelevelsistheWTtotheknockout.We
consistently observed that TLR3-deﬁcient mice developed
signiﬁcantly increased IL-4 and reduced IFN-γ, while TRIF-
deﬁcient mice developed signiﬁcantly increased IL-33 and
reduced IFN-β.
3.6. TLR3-Deﬁcient Mice Have Increased Markers of Alter-
native Macrophage Activation during Acute Myocarditis. To
conﬁrm that the increased IL-4 and decreased IFN-γ levels
that we had observed in the heart of TLR3-deﬁcient mice
during acute myocarditis were due to a shift to a classic Th2
response, we examined markers of IL-4-driven alternative
activation in the heart by qRT-PCR (Figure 7)[ 23, 24]. We
found that arginase-1 (Arg-1), chitinase (Ym1), the IL-4
receptor (IL-4R), and the macrophage mannose receptor
(Mrc1) were signiﬁcantly increased in TLR3-deﬁcient hearts
compared to WT controls (Figure 7), indicating a switch to a
Th2 response. Note the high-fold increase in Arg1 and Ym1
in TLR3-deﬁcient hearts compared to WT controls or TRIF-
deﬁcient mice (Figure 7). In contrast, these classical markers
of alternative activation were not increased in the heart of
TRIF-deﬁcient mice except for the macrophage mannose
receptor (Figure 7). These data show that TLR3-deﬁcient
mice switch to a Th2 response during CVB3 myocarditis,
while TRIF-deﬁcient mice develop a distinctly diﬀerent cyto-
kine response involving the Th2-associated cytokine IL-33.
3.7. IL-33 Decreases Cardiac Function in WT BL/6 Mice. Our
data showed that although TRIF-deﬁcient mice developed
similar myocarditis compared to TLR3-deﬁcient mice, they
had signiﬁcantly worse cardiac function. The elevation of IL-
33inTRIF-deﬁcientheartssuggestedthatthiscytokinecould
be responsible for increasing cardiac dysfunction in TRIF-
deﬁcient mice. We treated WT BL/6 mice with recombinant
rIL-33 or PBS on day 1 through 9pi following CVB3 infec-
tion on day 0 and examined heart function at day 10pi.
We found that rIL-33 treatment increased acute CVB3 myo-
carditis(Figures8(a)and8(c)),increasedcardiacIL-33levels
(Figure 8(b)), and decreased cardiac function at day 10 pi
(Figure 8(d)), indicating that elevated IL-33 in TRIF-def-
icient mice could lead to poor heart function in this strain.
3.8. IL-33 Improves Cardiac Dysfunction in TLR3-Deﬁcient
Mice during Acute Myocarditis. BecauseIL-33-treatment was
found to decrease cardiac function during acute CVB3 myo-
carditis in WT mice, we tested whether rIL-33 treatment of
TLR3-deﬁcient mice (that have a classic Th2 response) could
worsen myocarditis. rIL-33 was administered ip to TLR3-
deﬁcient mice every other day from day 1 to 9pi, as above,
and heart function examined at day 10pi. Surprisingly,
pressure-volume analysis of heart function showed that rIL-
33-treated TLR3-deﬁcient mice had signiﬁcantly improved
heart function during acute CVB3 myocarditis (Figure 9,
Table 2). Thus, in the context of a Th2-driven IL-4 response
elevated IL-33 protects the heart from cardiac dysfunction
during acute CVB3 myocarditis.
4. Discussion
Proinﬂammatory Th1 and Th17 immune responses are
known to be important in the pathogenesis of experimental
autoimmune myocarditis (EAM) and autoimmune CVB3
myocarditis mouse models [25–27]. Interestingly, Th2 res-
ponses have also been implicated in the pathogenesis of
autoimmune myocarditis promoting DCM and HF [2, 17,
28, 29]. Only Th2-type responding susceptible mouse strains
like BALB/c and A/J progress to chronic myocarditis and
DCM in EAM and CVB3 myocarditis models [9, 16]. Addi-
tionally, IFN-γ-deﬁcient mice, which have an elevated IL-
4/Th2 response, develop severe DCM and HF following
CVB3 myocarditis or EAM [17, 18]. Furthermore, IL-4 was
found to increase EAM using rIL-4 treatment or anti-IL-4
antibodies[2,28].EvidencesofarsuggeststhatIL-4increasesClinical and Developmental Immunology 7
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Figure 5: Cardiac function diﬀers between TLR3 deﬁcient (TLR3−/−) and TRIF−/− mice during acute and chronic CVB3 myocarditis.
(a) Representative pressure-volume loops for TLR3−/− (left) and TRIF−/− (right) hearts at day 10 pi compared to their WT controls. (b)
Comparison of pressure-volume relationships of TLR3−/−, TRIF−/− and WT mice at day 10 pi, n = 10 to 12 mice/group. Student’s t-test
compares TLR3−/− to TRIF−/− at day 0, 10 or 35 pi; ∗: P<0.05; ∗∗: P<0.01; ∗∗∗: P<0.001. ANOVA compared TLR3−/− to TRIF−/−
mice over time; †, P<0.05. EF: ejection fraction; dP/dT Max (mm Hg/s) measures the peak rate of pressure rise; ESP: end systolic pressure;
EDV: end diastolic volume.
autoimmune myocarditis by elevating autoantibody produc-
tion and activating mast cells and alternatively activated
macrophages that produce cytokines and enzymes needed
for remodeling and ﬁbrosis [2, 9, 17, 30–32].
In this study, TLR3-deﬁcient mice had signiﬁcantly in-
creased markers of alternative activation and switched from
IFN-γ to increased IL-4 production during acute CVB3
myocarditis, yet they did not develop severe DCM and HF.
ThissuggeststhatanIL-4-driven Th2responseisnot capable
on its own of inducing HF, at least not in resistant strains of
mice. Additionally, administration of rIL-33 to Th2-skewed
TLR3-deﬁcient mice reduced cardiac dysfunction during8 Clinical and Developmental Immunology
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Figure 6: TLR3-deﬁcient (TLR3−/−) mice have reduced IFN-γ and elevated IL-4 levels in the heart compared to WT B6.129 controls, while
TRIF−/− mice have reduced IFN-β and increased IL-33 com-pared to WT BL/6 mice by ELISA. Similar results were obtained in at least
three separate experiments and show the mean ± SEM of 7 to 12 mice/group. ∗: P<0.05; ∗∗: P<0.01.
acute myocarditis. IL-33 is known to be able to induce Th2
responses on its own or with IL-4, but IL-33 is unique in
that it can also increase proinﬂammatory Th1-type immune
responses [33]. Our data show that if IL-33 is elevated when
IL-4isnotalsohigh,ithasdeleteriousconsequencesonheart
function. We are currently investigating the mechanism of
action of IL-33, which is outside the scope of this paper.
Althoughthemechanismhasnotyetbeenelucidated,thedif-
ference in cardiac function and survival/HF between TLR3-
and TRIF-deﬁcient mice suggests that TLR4-mediated TRIFClinical and Developmental Immunology 9
Table 1: Similarity in cardiac function of C57BL/6 versus B6.129 mice prior to infection (day 0) and during acute (day 10) or chronic (day
35) CVB3 myocarditis based on pressure-volume analysis.
Day 0 Day 10 pi Day 35 pi
Parameter BL/6 B6.129 BL/6 B6.129 BL/6 B6.129
HR 591 ± 3.9 596 ± 3.7 535 ± 6.0 567 ± 11.5∗ 569 ± 9.0 601 ± 5.7∗∗
ESP 114 ± 2.1 111 ± 3.8 98 ± 2.1 108 ± 2.6∗∗ 109 ± 3.9 116 ± 3.4
EDP 6.3 ± 0.6 6.9 ± 2.5 4.1 ± 0.5 5.5 ± 0.5 4.8 ± 0.4 4.6 ± 0.7
dP/dT Max 11336 ± 463 10766 ± 250 10019 ± 538 10241 ± 395 11042 ± 852 10658 ± 555
dT/dT Min −10628 ± 290 −10022 ± 309 −8484 ± 306 −9549 ± 454 −10017 ± 528 10852 ± 432
EF 71 ± 4.3 74 ± 2.2 58 ± 3.5 66 ± 5.7 69 ± 4.4 69 ± 2.4
ESV 5.7 ± 1.1 4.0 ± 0.4 10 ± 1.1 7.4 ± 1.8 6 ± 1.0 4 ± 0.2
EDV 18 ± 1.2 16 ± 1.0 24 ± 1.2 18 ± 2.5 18 ± 1.7 14 ± 0.7
CO 7499 ± 408 6940 ± 318 7276 ± 495 6083 ± 485 6885 ± 672 5960 ± 417
Ees 9.2 ± 0.8 8.3 ± 0.9 7.5 ± 0.5 8.4 ± 1.0 11.5 ± 1.2 15 ± 1.4
Ea/Ees 1.05 ± 0.1 1.3 ± 0.2 1.0 ± 0.0 1.1 ± 0.2 0.9 ± 00 . 8 ± 0.06
V0 −7.7 ± 1.3 −11.3 ± 1.6 −5.4 ± 1.2 −6.4 ± 2.1 −4.2 ± 1.9 −5.6 ± 1.0
Tau 5.2 ± 0.2 5.1 ± 0.3 5.6 ± 0.2 5.6 ± 0.2 5.6 ± 0.2 5.1 ± 0.2
CO (μL/min), cardiac output; dP/dT Max, peak rate of pressure rise (mmHg/s); dP/dT Min, peak rate of pressure decline (mmHg/s); Ea/Ees, arterial elastance
normalized to Ees; EDP (mmHg), end diastolic pressure; EDV (μL), end diastolic volume; Ees (mmHg/μL), LV end systolic elastance (stiﬀness); EF (%),
ejectionfraction;ESP(mmHg),endsystolicpressure;ESV(μL),endsystolicvolume;HR(bmp),heartrate;PFR/EDV(s−1),peakﬂowratenormalizedtoEDV;
PMX/EDV2, maximum ventricular power normalized to EDV2 (mW/μL2) × 100; PRSW (mmHg), preload recruitable stroke work; SV (μL), stroke volume;
SW, stroke work; Tau, Weiss (ms), time constant of diastolic relaxation; V0 (μL), X-intercept of the ESP-volume relationship. ∗ : P<0.05, ∗∗ : P<0.01, and
∗∗∗ : P<0.001 compare BL/6 to B6.129 by Student’s t-test at each timepoint. Data shown as mean ± SEM for 10 mice/group per timepoint.
Table 2: In vivo hemodynamics of recombinant (r)IL-33-treated TLR3-deﬁcient mice during acute CVB3 myocarditis (day 10 pi) based on
pressure-volume analysis.
Parameter PBS rIL-33 P value
Heart rate 560 ± 12.0 555 ± 7.6 0.75
Developed pressure 66 ± 5.6 82 ± 3.9 0.04
EDP 11 ± 1.6 6 ± 0.8 0.04
dP/dT Max 4891 ± 537 7177 ± 523 0.01
dP/dT Min −3597 ± 446 −6168 ± 850 0.02
EF 54 ± 4.0 60 ± 2.8 0.24
ESV 8 ± 1.6 5 ± 1.7 0.27
EDV 17 ± 1.9 14 ± 3.2 0.34
CO 5.0 ± 0.43 4.5 ± 0.96 0.58
PMX 4 ± 0.7 6 ± 0.7 0.03
PRSW 35 ± 6.0 62 ± 11.2 0.04
Ees 5 ± 0.4 14 ± 1.0 0.00001
EM a x 1 3± 2.7 32 ± 3.9 0.002
Ea/Ees 1.7 ± 0.18 0.89 ± 0.19 0.01
CO, cardiac output (μL/min); dP/dT max, peak rate of pressure rise (mmHg/s); dP/dT min, peak rate of pressure decline (mmHg/s); EDV, end diastolic
volume (μL); Ees, LV end systolic elastance; EF, ejection fraction (%); developed pressure, (ESP-EDP) (mmHg); ESV, end systolic volume (μL); PRSW, preload
recruitable stroke work; PMX, maximum ventricular power (mW); Ea/Ees, arterial elastance normalized to Ees; E Max, slope of line from end systole to end
diastole. P values compare PBS-treated TLR3−/− to rIL-33-treated TLR3−/− by Student’s t-test at day 10 pi. Data are shown as mean ± SEM for 11 to 12
mice/group. All mice were infected with CVB3 10 days prior to assessment.
may be responsible for reducing the negative cardiac eﬀects
of IL-33 in the heart during acute CVB3 myocarditis. We
showed previously that more severe acute CVB3 myocarditis
in male BALB/c mice is associated with elevated TLR4+
IL-1β+ alternatively activated M2 macrophages in the heart
[34]. Perhaps elevated IL-33 negatively impacts heart dis-
ease by increasing a proinﬂammatory M2 macrophage
population in the heart leading to remodeling and HF. We
are currently investigating this possibility.
Previous reports have found that increased myocarditis
and HF in TLR3- or TRIF-deﬁcient mice is due primarily to
increased viral replication [11, 14]. However, this study sug-
gests that high viral replication does not necessarily result
in HF because TLR3-deﬁcient mice had high levels of viral10 Clinical and Developmental Immunology
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Figure 7: TLR3-deﬁcient (TLR3−/−) mice have increased markers
of IL-4-driven alternative activation compared to TRIF−/− mice.
Markers of alternative activation included arginase-1 (Arg1), chiti-
nase (Ym1), IL-4R, and macrophage mannose receptor (Mrc1) by
qRT-PCR. Relative gene expression (RGE) was normalized to hypo-
xanthinephosphoribosyltransferase1(HPRT).Datashowthemean
± SEM of 10 mice/group. ∗∗: P<0.01; ∗∗∗: P<0.001.
replication in the heart but were protected from severe chro-
nic disease and HF. These ﬁndings suggest that additional
factors beside direct viral damage are required for progres-
sion to DCM and HF such as elevated IL-33. IL-33 has been
called an “alarmin” because it acts as a nuclear transcription
f a c t o ru n t i li ti sr e l e a s e df r o md a m a g e dc e l l sw h e ni ta c t sa sa
cytokineviaitsreceptor[35].Weshowinthisstudythathigh
viral replication does not itself account for increased IL-33
levels in the heart during CVB3 myocarditis because similar
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Figure 8: Recombinant IL-33 treatment increases myocarditis and
cardiac dysfunction in BL/6 mice. Male BL/6 mice were treated with
recombinant IL-33 (rIL-33) or PBS every other day from day 1 to
9 pi and (a,c) myocarditis, (b) cardiac IL-33 levels by ELISA and
(d) heart function assessed using pressure-volume relationships at
day 10 pi. (c) Representative histology sections of inﬂammation in
PBS-treated (left) and rIL-33-treated (right) BL/6 mice stained with
H&E, magniﬁcation ×64. Data show the mean ± SEM of 10 mice/
group. ∗∗: P<0.01; ∗∗∗: P<0.001.
amounts of viral replication occurred in TLR3- and TRIF-
deﬁcienthearts,butIL-33levelswereonlyincreasedinTRIF-
deﬁcient mice. Because IL-33 is missing the signal peptide
sequencerequiredforsecretionasatraditionalcytokine[33],
perhaps TRIF regulates the level of IL-33 within cells and
then IL-33 is released by cellular damage due to viral replica-
tion thereby accounting for the diﬀerences in IL-33 levels
between knockout strains.
The major limitation to this study is that TLR3- and
TRIF-deﬁcient mice are on a diﬀerent background strain
(TLR3−/− BL/6 mice were not available when we started
these studies). Yet we provide evidence in this study that for
all major parameters WT BL/6 and B6.129 strains respond-
ed in a similar manner during acute and chronic CVB3 myo-
carditisandarethuscomparablebackgrounds.Thisevidence
includes (1) that both strains are “resistant” to the develop-
ment of the chronic phase of CVB3 myocarditis and DCMClinical and Developmental Immunology 11
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Figure 9: Summary of pressure-volume relationships at day 10pi
in TLR3−/− mice treated with recombinant IL-33 (rIL-33) or PBS
every other day from day 1 to 9pi. dP/dT Max measures the peak
rate of pressure rise (mmHg/s); Tau, time constant of diastolic
relaxation; EDP, end diastolic pressure; Ea/Ees, arterial elastance
normalized to Ees which is left ventricular end systolic elastance
(stiﬀness); PMX, maximum ventricular power; PRSW, preload
recruitable stroke work. n = 10 to 12 mice/group. ∗: P<0.05.
(Figures 2 and 5, Table 1), (2) that both strains have almost-
identical heart function prior to infection (Table 1,d a y0 ) ,
(3) that both strains have nearly identical heart function
as assessed by echocardiography and pressure-volume rela-
tionships during acute (day 10pi) and chronic (day 35pi)
CVB3 myocarditis (Figures 3 and 5, Table 1), (4) that the
severity and histologic appearance of acute myocarditis is
the same for both strains (Figure 1), (5) that the level of
viral replication in the heart during acute myocarditis is
the same for both strains (Figure 1), and (6) that there is
a similar level of M2 markers in the heart by RT-PCR for
bothWTstrains(Figure 7,notediﬀerenceinscale).However,
it is possible that important diﬀerences exist between these
backgrounds. We are currently examining this possibility by
assessing TLR3-deﬁcient mice on a BL/6 background.
In summary, we have shown in this study that elevated
IL-4 or IL-4 plus IL-33 in the context of a Th2-driven res-
ponse does not cause severe chronic disease resulting in HF.
Yet outside of a classic IL-4-driven Th2-response, IL-33 is
capable of causing cardiac dysfunction and HF as occurs in
TRIF-deﬁcient mice. Our ﬁndings suggest that the combina-
tion of high viral replication and elevated IL-33 levels in the
heart is likely to be important in the progression from acute
CVB3 myocarditis to severe DCM and HF. Our data also
suggests that activation of TLR3 and TRIF in response to
CVB3 infection protects Th1-responding mouse strains like
BL/6 and B6.129 from progressing to chronic myocarditis,
DCM, and HF. These ﬁndings provide insight into why
most individuals that acquire CVB3 infection do not develop
DCM and HF, and why polymorphisms in TLR3 signaling
may predispose certain individuals to develop viral myocar-
ditis, DCM, and HF.
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